Study Evaluating The Potential Interaction Between Verapamil Immediate Release And SAM-531 When Co-Administered
- Registration Number
- NCT00745576
- Lead Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
- Brief Summary
The purpose of this study is to evaluate the effects of multiple doses of verapamil on the plasma concentration of a single dose of SAM-531 in healthy young adult subjects and to assess the safety and tolerability of co-administration of SAM-531 and verapamil.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description 1 SAM-531 -
- Primary Outcome Measures
Name Time Method blood samples 7 weeks
- Secondary Outcome Measures
Name Time Method Safety based on supine vital signs evaluations, 12-lead ECGs and routine lab tests 7 weeks
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the pharmacokinetic mechanisms of SAM-531 and verapamil interaction in Alzheimer's disease?
How does verapamil modulate P-glycoprotein activity affecting SAM-531 bioavailability in phase 1 trials?
What biomarkers correlate with enhanced cognitive outcomes when combining calcium channel blockers and amyloid-targeting agents?
Are there comparative efficacy data between SAM-531 and other BACE1 inhibitors in early-stage Alzheimer's treatment?
What adverse event profiles are observed in co-administration of verapamil and experimental Alzheimer's therapies like SAM-531?